A previous study of XPD Lys751Gln in 166 advanced CRC patients receiving FOLFOX therapy found a negative relationship between XPD Gln/Gln genotype and adverse progression-free survival (HR  = 2.21, 95% CI  = 1.17–4.17, P  = 0.01) [34]. This evidence concerns the gene ERCC2 and colorectal carcinoma.